NPI: 1073988994 · ALBEMARLE, NC 28001 · General Acute Care Hospital · NPI assigned 12/03/2015
Authorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
| Authorized Official | DEFURIO, ANTHONY (CFO/EXECUTIVE VICE PRESIDENT) |
| NPI Enumeration Date | 12/03/2015 |
Other providers sharing the same authorized official: DEFURIO, ANTHONY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 33,650 | $1.57M |
| 2019 | 30,769 | $1.66M |
| 2020 | 20,331 | $1.02M |
| 2021 | 33,788 | $2.08M |
| 2022 | 34,399 | $2.71M |
| 2023 | 45,854 | $3.24M |
| 2024 | 36,659 | $2.86M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 24,530 | 22,816 | $5.60M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 21,148 | 19,607 | $4.49M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10,275 | 9,535 | $1.99M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3,385 | 3,187 | $507K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 9,010 | 8,364 | $275K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3,523 | 3,269 | $192K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,139 | 1,924 | $165K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9,152 | 8,491 | $155K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 20,335 | 18,718 | $149K |
| 71045 | Radiologic examination, chest; single view | 5,265 | 4,899 | $132K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5,042 | 4,374 | $130K |
| 80053 | Comprehensive metabolic panel | 15,014 | 13,922 | $123K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1,256 | 1,190 | $116K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 446 | 424 | $95K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 237 | 215 | $94K |
| 41899 | Unlisted procedure, dentoalveolar structures | 63 | 61 | $85K |
| J3490 | Unclassified drugs | 25,956 | 15,197 | $59K |
| 71046 | Radiologic examination, chest; 2 views | 2,261 | 2,137 | $55K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 103 | 101 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | 335 | 320 | $45K |
| 84484 | 5,230 | 4,816 | $37K | |
| 59025 | Fetal non-stress test | 556 | 422 | $36K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,522 | 1,331 | $36K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 137 | 122 | $35K |
| 83735 | 5,694 | 5,322 | $35K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1,042 | 405 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3,622 | 3,345 | $30K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,229 | 1,995 | $30K |
| 43235 | 194 | 181 | $29K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 137 | 134 | $27K |
| 83690 | 3,594 | 3,330 | $24K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 4,303 | 3,901 | $22K |
| 43450 | 224 | 218 | $21K | |
| 81025 | 2,330 | 2,125 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 557 | 486 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2,085 | 1,956 | $16K |
| 83605 | 1,733 | 1,620 | $16K | |
| 81003 | 7,178 | 6,661 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,790 | 1,607 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 26 | 25 | $12K |
| G0378 | Hospital observation service, per hour | 243 | 144 | $11K |
| 81001 | 2,842 | 2,624 | $10K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 44 | 44 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,245 | 2,064 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,738 | 1,607 | $8K |
| 87430 | 490 | 471 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 3,728 | 3,412 | $6K |
| J2704 | Injection, propofol, 10 mg | 2,340 | 2,201 | $5K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 8,463 | 4,480 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 207 | 189 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 266 | 213 | $4K |
| 82803 | 230 | 221 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,051 | 948 | $3K |
| 64636 | 13 | 13 | $3K | |
| 87070 | 241 | 230 | $3K | |
| 64635 | 13 | 13 | $3K | |
| 83880 | 120 | 115 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 118 | 111 | $2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 26 | 24 | $2K |
| 97597 | 49 | 25 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 1,250 | 1,163 | $2K |
| 99199 | Unlisted special service, procedure or report | 255 | 255 | $1K |
| 81002 | 367 | 337 | $1K | |
| 85027 | 185 | 176 | $948.92 | |
| 80047 | 110 | 98 | $866.94 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 568 | 544 | $863.78 |
| 87081 | 99 | 97 | $639.02 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 14 | 12 | $612.05 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 14 | 12 | $612.05 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 349 | 260 | $555.91 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 13 | 12 | $554.00 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 25 | 25 | $492.33 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 265 | 246 | $422.88 |
| Q3014 | Telehealth originating site facility fee | 115 | 70 | $421.19 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 216 | 184 | $419.38 |
| 94761 | 24 | 12 | $389.41 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 140 | 131 | $366.41 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 89 | 87 | $329.58 |
| J1790 | Injection, droperidol, up to 5 mg | 89 | 85 | $328.29 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 122 | 111 | $295.58 |
| 82550 | 62 | 61 | $278.94 | |
| 82962 | 204 | 196 | $265.20 | |
| 80076 | 31 | 29 | $234.78 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 48 | 48 | $148.93 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 192 | 188 | $103.74 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 229 | 215 | $96.88 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 68 | 66 | $91.27 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 37 | 36 | $84.85 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 158 | 128 | $59.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 13 | 13 | $59.15 |
| A9150 | Non-prescription drugs | 49 | 27 | $55.61 |
| J8540 | Dexamethasone, oral, 0.25 mg | 55 | 50 | $45.08 |
| 94760 | 13 | 12 | $29.46 | |
| 85610 | 14 | 14 | $24.50 | |
| 84100 | 12 | 12 | $23.64 | |
| A9270 | Non-covered item or service | 1,814 | 1,151 | $1.56 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 17 | 12 | $0.00 |